Castle Biosciences (CSTL) Return on Invested Capital (2019 - 2026)

Castle Biosciences has reported Return on Invested Capital for 6 years, with the latest figure at 0.07% in Q2 2026.

• Quarterly Return on Invested Capital rose 1.0% year-over-year to 0.07% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.07% (up 1.0% YoY) and the FY2025 annual result came in at 0.85%, changed N/A from the prior year.
• Return on Invested Capital slipped to 0.07% in Q2 2026 per CSTL's latest filing, from 0.06% in the prior quarter.
• Over five years, Return on Invested Capital peaked at 0.02% in Q2 2022 and troughed at 0.33% in Q1 2025.
• A 3-year average of 0.09% and a median of 0.06% in 2025 frame the typical range for Return on Invested Capital.
• The sharpest annual moves came in 2022 and 2026: Return on Invested Capital decreased 1 bps in 2022, then increased 26 bps in 2026.
• Over 3 years, Return on Invested Capital stood at 0.03% in 2022, then plunged by 196 bps to 0.1% in 2025, then gained by 29 bps to 0.07% in 2026.
• According to Business Quant data, Return on Invested Capital over the past three periods registered 0.07%, 0.06%, and 0.1% for Q2 2026, Q1 2026, and Q4 2025 respectively.